BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33729861)

  • 1. Metastasis of Sarcomatoid Malignant Mesothelioma With
    Chen KB; Huang YJ; Huang Y; Wu ZW; Jin XL; Zhang H; Xiang XP; Chen L; Chen L
    Int J Surg Pathol; 2021 Dec; 29(8):856-863. PubMed ID: 33729861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
    Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
    Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.
    Yoshida M; Jimbo N; Tsukamoto R; Itoh T; Kawahara K; Mitsui S; Tanaka Y; Maniwa Y
    Diagn Pathol; 2023 Nov; 18(1):126. PubMed ID: 38017544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases.
    Oramas DM; Zaleski M; Moran CA
    Int J Surg Pathol; 2021 Dec; 29(8):820-825. PubMed ID: 33939493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleural mesothelioma classification-update and challenges.
    Dacic S
    Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
    Wu D; Hiroshima K; Matsumoto S; Nabeshima K; Yusa T; Ozaki D; Fujino M; Yamakawa H; Nakatani Y; Tada Y; Shimada H; Tagawa M
    Am J Clin Pathol; 2013 Jan; 139(1):39-46. PubMed ID: 23270897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
    Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
    Minami K; Jimbo N; Tanaka Y; Hokka D; Miyamoto Y; Itoh T; Maniwa Y
    Virchows Arch; 2020 Mar; 476(3):469-473. PubMed ID: 31667596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
    Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleural mesothelioma classification update.
    Beasley MB; Galateau-Salle F; Dacic S
    Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural mesothelioma metastasis of the scalp.
    Bicak T; Ozekinci S; İbiloğlu İ
    Pol J Pathol; 2023; 74(4):297-301. PubMed ID: 38477094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
    Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Autopsy case of sarcomatoid malignant pleural mesothelioma].
    Ogura H; Naoki K; Togashi I; Kunikane H; Okamoto H; Hida N; Narita Y; Kase M; Oosawa H; Oomori T; Watanabe K
    Nihon Kokyuki Gakkai Zasshi; 2006 Oct; 44(10):689-94. PubMed ID: 17087333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
    Chapel DB; Schulte JJ; Berg K; Churg A; Dacic S; Fitzpatrick C; Galateau-Salle F; Hiroshima K; Krausz T; Le Stang N; McGregor S; Nabeshima K; Husain AN
    Mod Pathol; 2020 Feb; 33(2):245-254. PubMed ID: 31231127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p16 Deletion in sarcomatoid tumors of the lung and pleura.
    Tochigi N; Attanoos R; Chirieac LR; Allen TC; Cagle PT; Dacic S
    Arch Pathol Lab Med; 2013 May; 137(5):632-6. PubMed ID: 23627453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues.
    Mizuhashi K; Okamoto K; Nabeshima K; Kishimoto T
    BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38341199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.